moneyheap
ELAN · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Elanco Animal Health Incorporated Common Stock (ELAN) stock moving?
Elanco reported a Q3 2026 beat on Nov 6, with adjusted EPS of $0.27 against a $0.20 estimate and sales of $1.265B against $1.208B, driven by Pet Health demand and pricing. It raised full-year 2026 adjusted EPS guidance to $1.17-$1.20 (from $1.10-$1.16) and sales guidance to $5.155B-$5.180B, both above consensus. Q4 guidance was roughly in line with estimates, which limits the near-term upside from the report. The stock fell to $23.68 on Nov 5 before the report, then jumped on Nov 6 to a $25.74 close on about 11.5M shares, roughly 2.5 times the late-October average. It has kept climbing and closed at $26.76 on Nov 10, about 16% above the Oct 30 close of $23.06. J.P. Morgan maintained its Overweight rating and raised its target to $35 on Nov 9, while Morgan Stanley's Equal-Weight rating and $25 target now sit below the share price. A Nov 6 consumer survey supports the view that pet owners keep spending on pet health. The 30-day price move already reflects much of the beat-and-raise, so further gains depend on Q4 delivery and the sustainability of pricing.
News behind the analysis
- JP Morgan Maintains Overweight on Elanco Animal Health, Raises Price Target to $35J.P. Morgan kept its Overweight rating and raised its price target to $35 from $33 after the Q3 results.
- J.P. Morgan Maintains Buy Rating and Raises Price Target for Elanco Animal HealthAnalyst Chris Schott kept a Buy rating on ELAN and lifted the price target from $33 to $35.
- Elanco Animal Health Reports Third Quarter 2026 Financial ResultsQ3 revenue reached $1.265 billion with adjusted EPS of $0.27, and full-year 2026 guidance was updated.
- Elanco Animal Health Q3 Adj. EPS $0.27 Beats $0.20 Estimate, Sales $1.265B Beat $1.208B EstimateAdjusted EPS of $0.27 beat the $0.20 estimate, and sales of $1.265B beat the $1.208B estimate.
- Elanco Animal Health Raises FY2026 Adj EPS Guidance from $1.10-$1.16 to $1.17-$1.20 vs $1.13 Est; Raises FY2026 Sales Guidance from $5.090B-$5.140B to $5.155B-$5.180B vs $5.132B EstFull-year 2026 adjusted EPS guidance was raised to $1.17-$1.20 and sales guidance to $5.155B-$5.180B, both above consensus.
- Elanco Animal Health Sees Q4 Adj EPS $0.16-$0.19 vs $0.18 Est; Sees Sales $1.190B-$1.215B vs $1.193B EstQ4 2026 adjusted EPS guidance of $0.16-$0.19 brackets the $0.18 estimate, and sales guidance of $1.190B-$1.215B is in line with the $1.193B estimate.
- Elanco Animal Health Sees Strong Momentum Heading Into 2027Elanco beat Q3 earnings and revenue estimates, citing Pet Health demand and pricing gains, and raised its full-year 2026 outlook.
- Elanco Releases Consumer Research Affirming Resilience of Pet Health SpendingA U.S. consumer survey found pet owners keep prioritizing pet health spending despite macroeconomic pressures.
- Morgan Stanley Maintains Equal-Weight on Elanco Animal Health, Lowers Price Target to $25Morgan Stanley kept an Equal-Weight rating and cut its price target to $25 before the Q3 report.
About Elanco Animal Health Incorporated Common Stock
Elanco Animal Health is an Indianapolis-based company that makes medicines, vaccines and parasite treatments for pets and farm animals. It was spun out of Eli Lilly in 2018–2019 and is one of the largest pure-play animal health companies. It is now pushing newer pet drugs such as Zenrelia (for itchy skin in dogs), Credelio Quattro (a parasite pill) and Befrena (an allergy injection for dogs).
How it makes money
Elanco sells products to veterinarians, distributors, retailers and livestock producers. Revenue is split fairly evenly between Pet Health (roughly 53%: parasite control, skin and allergy treatments, other pet medicines) and Farm Animal (roughly 47%: products for cattle, poultry, pigs and aquaculture). Full-year 2026 revenue guidance is about $5.1 billion. The company carries a lot of debt, and lowering that debt (net leverage was about 3.1x adjusted EBITDA in mid-2026) is one of its main financial goals.
What usually moves ELAN
- Sales uptake of new pet products (Zenrelia, Credelio Quattro, Befrena)
- Competition in pet dermatology and parasiticides
- Livestock economics and protein demand
- Debt reduction and leverage ratio
- Currency swings on international sales